Ornithine-δ-aminotransferase clinical trials at UCSF
1 in progress, 0 open to eligible people
Showing trials for
Gyrate Atrophy Ocular and Systemic Study
Sorry, not yet accepting patients
The Gyrate Atrophy Ocular and Systemic Study characterizes the natural history of ornithine levels and retinal degeneration (RD) associated with disease-causing OAT variants in the presence of standard care dietary treatment regimens over 4 years. The research goal is to understand the impact of OAT mutations on plasma ornithine levels and retinal degeneration.
San Francisco, California and other locations
Our lead scientists for Ornithine-δ-aminotransferase research studies include Jacque Duncan, MD.